8-K: STAAR Surgical Appoints Interim Co-CEOs Amid CEO Search

STAAR Surgical Company has appointed Warren Foust and Deborah Andrews as Interim Co-Chief Executive Officers following the departure of Stephen C. Farrell, initiating a global search for a permanent CEO.

Summary

• Stephen C. Farrell stepped down as Chief Executive Officer of STAAR Surgical Company, effective January 31, 2026.
• Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, have been appointed Interim Co-Chief Executive Officers, effective February 1, 2026.
• The Board of Directors has established a Search Committee to conduct a global search for a new Chief Executive Officer, considering both internal and external candidates.
• Each Interim Co-CEO received an equity award of restricted stock units (RSUs) with a grant date fair value of $375,000, vesting on August 1, 2026.
• Mr. Foust's letter agreement outlines additional compensation and benefits if he is not offered the permanent CEO position and resigns under specific conditions, including accelerated vesting of certain equity awards and a $250,000 cash payment if terminated before March 28, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative development due to the CEO's departure and the inherent uncertainty of an interim leadership period, despite the structured approach to finding a replacement.

Positives

• Appointment of two experienced internal leaders, Warren Foust (President and COO) and Deborah Andrews (CFO), as Interim Co-CEOs ensures business continuity during the transition.
• The Board has promptly established a Search Committee with named directors to conduct a global search for a permanent CEO, indicating a structured approach to leadership transition.
• Both interim leaders have extensive experience within STAAR Surgical and the broader medical device/ophthalmic industry, providing stability.

Negatives

• The departure of the previous Chief Executive Officer, Stephen C. Farrell, creates a leadership void and potential uncertainty.
• The interim nature of the Co-CEO roles suggests a period of transition, which can sometimes lead to a temporary slowdown in strategic initiatives or decision-making.
• The detailed severance and additional compensation package for Mr. Foust, contingent on not being offered the CEO role, highlights the potential for further executive changes and associated costs.

Risks

• Leadership Transition Risk: The period of interim leadership and the search for a new CEO could introduce uncertainty regarding the company's future strategic direction and operational execution.
• Executive Retention Risk: If Mr. Foust is not appointed permanent CEO, there is a risk of his departure, potentially impacting the company's operational leadership.
• Integration Risk: A new CEO, especially an external candidate, may require time to integrate and fully understand the company's operations and culture, potentially causing temporary disruptions.

Future Outlook

The company is actively conducting a global search for its next Chief Executive Officer, considering both internal and external candidates, with the aim of appointing a permanent leader to guide its future strategic direction. The interim co-CEOs are expected to ensure business continuity during this transition period, which is anticipated to conclude by August 1, 2026, or earlier upon the appointment of a new CEO.

Management Comments

• "Warren and Deborah are respected and qualified leaders with deep knowledge of STAAR and our industry. The entire Board is confident in their ability to ensure business continuity and lead our Company during this period of transition." Neal C. Bradsher, Chairman of the Board.
• "The Board is committed to working diligently to identify and appoint a new CEO." Neal C. Bradsher, Chairman of the Board.

Industry Context

StockSavvy.ai notes that leadership transitions, especially at the CEO level, are common in the medical device and ophthalmology sectors, often driven by strategic shifts, performance pressures, or board-level agreements. The appointment of internal executives as interim co-CEOs is a standard practice to maintain stability and operational momentum while a comprehensive search is underway. This approach minimizes disruption compared to bringing in an immediate external interim leader.

Comparison to Industry Standards

• The appointment of internal executives as interim leaders is a common practice in the medical device industry, similar to how companies like Medtronic or Johnson & Johnson might manage leadership transitions to ensure continuity.
• The establishment of a dedicated Search Committee, composed of independent directors, aligns with best corporate governance practices observed in major public companies, ensuring a thorough and objective selection process for the next CEO.
• The compensation structure for interim roles, including equity awards and severance provisions, is typical for senior executives taking on additional responsibilities during a critical transition, comparable to arrangements seen at other NASDAQ-listed biotechnology or medical technology firms.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: May experience short-term uncertainty due to leadership transition, but the structured search and experienced interim leaders aim to mitigate long-term concerns. The cooperation agreement with Broadwood Partners suggests shareholder activism may have influenced the change.
• Employees: The appointment of internal leaders as interim Co-CEOs could provide a sense of stability, but the ongoing search for a permanent CEO might create some internal uncertainty regarding future strategic direction.
• Customers/Suppliers: Unlikely to see immediate direct impact, as day-to-day operations are expected to continue under experienced interim leadership.

Next Steps

• The Search Committee will continue its global search for STAAR Surgical's next Chief Executive Officer, evaluating both internal and external candidates.
• The interim co-CEOs, Warren Foust and Deborah Andrews, will lead the company and manage day-to-day operations during the transition period.
• The company will make a public announcement of the appointment of a new Chief Executive Officer.

Key Dates

Recommendation

The departure of a CEO typically introduces uncertainty, which can lead to short-term stock volatility. However, the appointment of experienced internal executives as interim co-CEOs and the immediate initiation of a structured global search for a permanent CEO demonstrate a proactive approach to leadership transition. This measured response, coupled with the company's established position as a global leader in phakic IOLs, suggests that while there's a period of transition, the underlying business fundamentals are likely stable. An investor would likely hold, awaiting clarity on the permanent CEO appointment and any subsequent strategic direction.

Keywords

STAAR Surgical, CEO change, Interim CEO, Executive appointment, Corporate governance, Leadership transition, Ophthalmic surgery, EVO ICL, Phakic IOLs, NASDAQ: STAA